

What is claimed is:

1. A method of restoring normal hemostasis in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.
2. A method of restoring normal hemostasis in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition prepared by a process comprising incubating platelets with an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, to form the composition, wherein the subject has been treated or is being treated with an antiplatelet agent.
3. A method of treating a coagulopathy in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.
4. A method of treating a coagulopathy in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition prepared by a process comprising incubating platelets with an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, to form the composition, wherein the subject has been treated or is being treated with an antiplatelet agent.
5. A method of preparing a subject for surgery, the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

6. A method of preparing a subject for surgery, the method comprising administering to the subject in need thereof an effective amount of a composition prepared by a process comprising incubating platelets with an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, to form the composition, wherein the subject has been treated or is being treated with an antiplatelet agent.
7. The method of any one of claims 5-6, wherein the surgery is an emergency surgery.
8. The method of any one of claims 5-6, wherein the surgery is a scheduled surgery.
9. The method of any one of claims 1-8, wherein the subject is being treated with an antiplatelet agent.
10. The method of claim 9, wherein treatment with the antiplatelet agent is stopped.
11. The method of claim 9, wherein treatment with the antiplatelet agent is continued.
12. A method of ameliorating the effects of an antiplatelet agent in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.
13. A method of ameliorating the effects of an antiplatelet agent in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition prepared by a process comprising incubating platelets with an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, to form the composition.
14. The method of claim 12 or claim 13, wherein the effects of the antiplatelet agent are the result of an overdose of the antiplatelet agent.

15. The method of any one of claims 1-14, wherein the composition further comprises an anti-fibrinolytic agent.
16. The method of claim 15, wherein the anti-fibrinolytic agent is selected from the group consisting of ϵ -aminocaproic acid (EACA), tranexamic acid, aprotinin, aminomethylbenzoic acid, fibrinogen, and a combination thereof.
17. The method of claim 15 or claim 16, wherein the platelets or platelet derivatives are loaded with the anti-fibrinolytic agent.
18. The method of any one of claims 1-17, wherein the antiplatelet agent is selected from the group consisting of aspirin, cangrelor, ticagrelor, clopidogrel, prasugrel, eptifibatide, tirofiban, abciximab, a supplement, and a combination thereof.
19. The method of any one of claims 1-17, wherein the antiplatelet agent is selected from the group consisting of aspirin, cangrelor, ticagrelor, clopidogrel, prasugrel, eptifibatide, tirofiban, abciximab, terutroban, picotamide, elinogrel, ticlopidine, ibuprofen, vorapaxar, atopaxar, and a combination thereof.
20. The method of any one of claims 1-17, wherein the antiplatelet agent is selected from the group consisting of aspirin, cangrelor, ticagrelor, clopidogrel, prasugrel, eptifibatide, tirofiban, abciximab, terutroban, picotamide, elinogrel, ticlopidine, ibuprofen, vorapaxar, atopaxar, cilostazol, prostaglandin E1, epoprostenol, dipyridamole, treprostinil sodium, sarpogrelate, and a combination thereof.
21. The method of any one of claims 1-20, wherein administering comprises administering topically.
22. The method of any one of claims 1-20, wherein administering comprises administering parenterally.

23. The method of any one of claims 1-20, wherein administering comprises administering intravenously.
24. The method of any one of claims 1-20, wherein administering comprises administering intramuscularly.
25. The method of any one of claims 1-20, wherein administering comprises administering intrathecally.
26. The method of any one of claims 1-20, wherein administering comprises administering subcutaneously.
27. The method of any one of claims 1-20, wherein administering comprises administering intraperitoneally.
28. The method of any one of claims 1-27, wherein the composition is dried prior to the administration step.
29. The method of claim 28, wherein the composition is rehydrated following the drying step.
30. The method of any one of claims 1-28, wherein the composition is freeze-dried prior to the administration step.
31. The method of claim 30, wherein the composition is rehydrated following the freeze-drying step.
32. The method of any one of claims 1-31, wherein the incubating agent comprises one or more salts selected from phosphate salts, sodium salts, potassium salts, calcium salts, magnesium salts, and a combination of two or more thereof.

33. The method of any one of claims 1-32, wherein the incubating agent comprises a carrier protein.
34. The method of any one of claims 1-33, wherein the buffer comprises HEPES, sodium bicarbonate (NaHCO_3), or a combination thereof.
35. The method of any one of claims 1-34, wherein the composition comprises one or more saccharides.
36. The method of claim 35, wherein the one or more saccharides comprise trehalose.
37. The method of claim 35 or claim 36, wherein the one or more saccharides comprise polysucrose.
38. The method of any one of claims 35-37, wherein the one or more saccharides comprise dextrose.
39. The method of any one of claims 1-38, wherein the composition comprises an organic solvent.
40. The method of any of claims 1-39, wherein the platelets or platelet derivatives comprise thrombosomes.